{"analyses":[{"ciLowerLimit":"0.79","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.08","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.30","paramType":"Hazard Ratio (HR)","paramValue":"0.92","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.2","upperLimit":"11.3","value":"10.0"},{"groupId":"OG001","lowerLimit":"9.5","upperLimit":"12.3","value":"10.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"320"},{"groupId":"OG001","value":"368"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive bevacizumab 5 mg/kg IV every two weeks and then receive either FOLFOX or FOLFIRI every two weeks as described in the intervention section. One cycle is defined as 8 weeks of treatment. Treatment continues until disease progression, unacceptable toxicity or surgery with curative intent as planned.\n\nFOLFOX or: Patients receive oxaliplatin 85 mg/m\\^2 IV infused over two hours followed by leucovorin 400 mg/m\\^2 IV over 2 hours followed by 5-FU 400 mg/m\\^2 IV bolus, then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours\n\nFOLFIRI: Patients receive irinotecan 180 mg/m\\^2 IV infused over 90 minutes followed by leucovorin 400 mg/m\\^2 IV over 2 hours followed by 5-FU 400 mg/m\\^2 IV bolus following leucovorin then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours.","id":"OG000","title":"Arm A: FOLFOX or FOLFIRI + Bevacizumab"},{"description":"Patients receive cetuximab 400mg/m\\^2 IV over 2 hours on the first day of treatment, then 250 mg/m\\^2 IV over 1 hour weekly thereafter. Patients also receive either FOLFOX or FOLFIRI every two weeks as described in the intervention section. One cycle is defined as 8 weeks of treatment. Treatment continues until disease progression, unacceptable toxicity or surgery with curative intent as planned.\n\nFOLFOX or: Patients receive oxaliplatin 85 mg/m\\^2 IV infused over two hours followed by leucovorin 400 mg/m\\^2 IV over 2 hours followed by 5-FU 400 mg/m\\^2 IV bolus, then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours\n\nFOLFIRI: Patients receive irinotecan 180 mg/m\\^2 IV infused over 90 minutes followed by leucovorin 400 mg/m\\^2 IV over 2 hours followed by 5-FU 400 mg/m\\^2 IV bolus following leucovorin then 2400 mg/m\\^2 continuous IV infusion over 46-48 hours.","id":"OG001","title":"Arm B: FOLFOX or FOLFIRI + Cetuximab"}],"paramType":"MEDIAN","populationDescription":"Only patients that recorded a response were included in analysis","reportingStatus":"POSTED","timeFrame":"Up to 5 years post-treatment","title":"Duration of Tumor Response","type":"SECONDARY","unitOfMeasure":"months"}